Characteristics | uOR | 95% CI | aOR | 95% CI | p value* |
---|---|---|---|---|---|
Pre-existing chronic conditions | Ìý | Ìý | Ìý | Ìý | Ìý |
 chronic lung disease | 2.41 | (1.67, 3.48) | 1.64 | (1.09, 2.46) | 0.017 |
 sleep apnea | 1.42 | (1.14, 1.76) | 1.17 | (0.93, 1.49) | 0.186 |
 a²õ³Ù³ó³¾²¹ | 1.59 | (1.29, 1.95) | 1.22 | (0.98, 1.52) | 0.072 |
 chronic heart disease | 1.17 | (0.83, 1.64) | 0.88 | (0.61, 1.27) | 0.502 |
 d¾±²¹²ú±ð³Ù±ð²õ | 1.12 | (0.85, 1.46) | 0.87 | (0.66, 1.17) | 0.360 |
 chronic kidney disease | 1.13 | (0.71, 1.80) | 0.95 | (0.55, 1.65) | 0.865 |
 high blood pressure | 1.36 | (1.16, 1.59) | 1.35 | (1.13, 1.62) | &±ô³Ù; 0.001 |
 chronic blood disorder | 1.18 | (0.59, 2.36) | 0.66 | (0.30, 1.45) | 0.299 |
 o²õ³Ù±ð´Ç±è´Ç°ù´Ç²õ¾±²õ | 1.08 | (0.72, 1.62) | 0.58 | (0.39, 0.87) | 0.009 |
 back problems | 1.62 | (1.36, 1.93) | 1.11 | (0.91, 1.36) | 0.321 |
 urinary incontinence | 1.33 | (0.96, 1.85) | 0.91 | (0.65, 1.27) | 0.563 |
 bowel disorder | 1.71 | (1.29, 2.26) | 1.06 | (0.81, 1.40) | 0.658 |
 weakened immune system | 2.35 | (1.76, 3.12) | 1.46 | (1.08, 1.98) | 0.015 |
 chronic neurological disorder | 1.73 | (1.10, 2.70) | 0.94 | (0.60, 1.49) | 0.801 |
 chronic fatigue syndrome or fibromyalgia | 4.57 | (3.00, 6.97) | 2.20 | (1.39, 3.50) | &±ô³Ù; 0.001 |
 s³Ù°ù´Ç°ì±ð | 1.06 | (0.58, 1.94) | 0.77 | (0.40, 1.50) | 0.446 |
 mental health condition | 1.64 | (1.39, 1.95) | 1.12 | (0.93, 1.35) | 0.238 |
 a°ù³Ù³ó°ù¾±³Ù¾±²õ | 1.7 | (1.44, 2.00) | 1.28 | (1.04, 1.56) | 0.019 |
Age at infection (ref = 15–34) | - | - | - | - | &±ô³Ù; 0.001 |
 35–49 | 1.02 | (0.90, 1.16) | 1.04 | (0.91, 1.19) | 0.540 |
 50–64 | 1.10 | (0.96, 1.26) | 0.96 | (0.83, 1.12) | 0.632 |
 65+ | 0.87 | (0.74, 1.02) | 0.66 | (0.54, 0.81) | &±ô³Ù; 0.001 |
Sex (ref = male) | - | - | - | - | &±ô³Ù; 0.001 |
 f±ð³¾²¹±ô±ð | 1.44 | (1.29, 1.60) | 1.30 | (1.15, 1.46) | &±ô³Ù; 0.001 |
Ethnicity (ref = white) | - | - | - | - | 0.023 |
 I²Ô»å¾±²µ±ð²Ô´Ç³Ü²õ | 1.26 | (0.97, 1.64) | 1.10 | (0.84, 1.46) | 0.487 |
 South Asian | 0.97 | (0.71, 1.32) | 0.94 | (0.68, 1.31) | 0.715 |
 East/Southeast Asian | 0.64 | (0.51, 0.80) | 0.63 | (0.49, 0.80) | &±ô³Ù; 0.001 |
 B±ô²¹³¦°ì | 0.90 | (0.57, 1.44) | 0.81 | (0.50, 1.31) | 0.387 |
 Arab/West Asian | 0.73 | (0.48, 1.10) | 0.73 | (0.47, 1.15) | 0.176 |
 Latin American | 0.87 | (0.56, 1.34) | 0.89 | (0.58, 1.38) | 0.604 |
 M¾±³æ±ð»å/°¿³Ù³ó±ð°ù | 1.09 | (0.80, 1.47) | 1.09 | (0.79, 1.51) | 0.600 |
Ethno-cultural composition (ref = first quintile)a | - | - | - | - | 0.001 |
 s±ð³¦´Ç²Ô»å | 1.27 | (1.07, 1.51) | 1.26 | (1.05, 1.52) | 0.013 |
 t³ó¾±°ù»å | 1.21 | (1.03, 1.42) | 1.19 | (1.00, 1.42) | 0.050 |
 f´Ç³Ü°ù³Ù³ó | 1.40 | (1.19, 1.64) | 1.43 | (1.20, 1.70) | &±ô³Ù; 0.001 |
 fifth (highest) | 1.20 | (0.99, 1.44) | 1.38 | (1.12, 1.69) | 0.002 |
 u²Ô°ì²Ô´Ç·É²Ô | 1.37 | (1.11, 1.70) | 1.43 | (1.11, 1.84) | 0.006 |
Situational vulnerability (ref = first quintile)b | - | - | - | - | &±ô³Ù; 0.001 |
 s±ð³¦´Ç²Ô»å | 0.96 | (0.82, 1.13) | 0.98 | (0.82, 1.16) | 0.782 |
 t³ó¾±°ù»å | 1.02 | (0.87, 1.19) | 0.96 | (0.81, 1.14) | 0.639 |
 f´Ç³Ü°ù³Ù³ó | 1.06 | (0.90, 1.25) | 0.99 | (0.83, 1.18) | 0.902 |
 fifth (highest) | 0.78 | (0.65, 0.93) | 0.68 | (0.56, 0.83) | &±ô³Ù; 0.001 |
 u²Ô°ì²Ô´Ç·É²Ôc | 1.09 | (0.89, 1.33) | - | - | - |
Pre-existing chronic health symptoms | Ìý | Ìý | Ìý | Ìý | Ìý |
 f²¹³Ù¾±²µ³Ü±ð | 1.98 | (1.70, 2.29) | 1.22 | (1.00, 1.48) | 0.047 |
 loss of appetite | 3.08 | (1.94, 4.89) | 1.82 | (1.12, 2.94) | 0.016 |
Number of pre-existing chronic health symptoms (ref = 0) | - | - | - | - | &±ô³Ù; 0.001 |
 1 or 2 | 1.29 | (1.11, 1.47) | 1.21 | (1.06, 1.38) | 0.005 |
 3 | 1.74 | (1.43, 2.11) | 1.56 | (1.26, 1.93) | &±ô³Ù; 0.001 |
 &²µ³Ù; 3 | 2.21 | (1.92, 2.54) | 1.47 | (1.20, 1.81) | &±ô³Ù; 0.001 |
Months since last vaccine dose prior to the month of infection (ref = 3 months or less) | - | - | - | - | &±ô³Ù; 0.001 |
 not vaccinated | 1.96 | (1.67, 2.30) | 1.54 | (1.19, 2.00) | 0.001 |
 4–6 months | 1.23 | (1.08, 1.40) | 1.31 | (1.15, 1.50) | &±ô³Ù; 0.001 |
 > 6 months | 1.22 | (1.02, 1.46) | 1.27 | (1.05, 1.52) | 0.013 |
 u²Ô°ì²Ô´Ç·É²Ô | 1.11 | (0.76, 1.61) | 1.01 | (0.71, 1.44) | 0.960 |
Time period of first infection (ref = pre-omicron) | - | - | - | - | 0.005 |
 Omicron (December 1, 2021 – date of electronic questionnaire completion) | 0.57 | (0.50, 0.66) | 0.70 | (0.55, 0.90) | 0.005 |
 u²Ô°ì²Ô´Ç·É²Ô | 1.14 | (0.42, 3.11) | 1.83 | (0.62, 5.36) | 0.271 |
Household member testing positive for SARS-CoV-2 infection (ref = no) | - | - | - | - | &±ô³Ù; 0.001 |
 y±ð²õ | 0.76 | (0.68, 0.85) | 0.83 | (0.74, 0.94) | 0.002 |
 u²Ô°ì²Ô´Ç·É²Ô | 1.42 | (0.73, 2.77) | 1.71 | (0.88, 3.34) | 0.116 |